Metformin/rosuvastatin - BC World Pharm

Drug Profile

Metformin/rosuvastatin - BC World Pharm

Alternative Names: BCWP-C001; BCWP_C001

Latest Information Update: 27 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BC World Pharm
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipidaemia

Most Recent Events

  • 10 Jul 2017 BC World Pharm completes a phase I trial in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT01992211)
  • 01 Dec 2016 BC World Pharm completes a phase I trial in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT01992211)
  • 09 Jul 2016 Phase-I clinical trials in Hyperlipidaemia (In volunteers) in South Korea (PO) prior to July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top